Ardelyx, Inc. (NASDAQ:ARDX) Q1 2025 Earnings Call Transcript
Operator: Good day everyone and welcome to the Ardelyx’s First Quarter 2025 Earnings. All participants will be in a listen-only mode.
Ardelyx Inc. (ARDX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 8,383,809 | $41,164,504 | +7202% | 0.05% |
| 2. | Millennium Management Israel Englander | 6,465,262 | $31,744,436 | +119% | 0.02% |
| 3. | Citadel Investment Group Ken Griffin | 3,190,355 | $15,664,643 | +29% | 0% |
| 4. | Two Seas Capital Sina Toussi | 2,120,337 | $10,410,855 | +15% | 0.33% |
| 5. | D E Shaw D. E. Shaw | 1,916,525 | $9,410,138 | +31% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.69 | 200,000 | Director | 2,696,871 | 2025-06-09 | Filing | |
| $3.29 | 100,000 | Director | 2,496,871 | 2025-05-15 | Filing | |
| $4.22 | 381,377 | Director | 2,396,871 | 2025-05-02 | Filing | |
| $5.00 | 77,729 | Director | 2,015,494 | 2025-02-24 | Filing | |
| $4.99 | 199,000 | Director | 1,937,765 | 2025-01-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.08 | 6,421 | Officer | 402,583 | 2025-05-20 | Filing | |
| $4.08 | 7,218 | Officer | 416,089 | 2025-05-20 | Filing | |
| $4.08 | 46,817 | Officer, Director | 1,547,937 | 2025-05-20 | Filing | |
| $4.08 | 14,522 | Officer | 282,158 | 2025-05-20 | Filing | |
| $4.08 | 5,992 | Officer | 311,731 | 2025-05-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,977,006 | $122,947,690 | 0.07% | |
| 2. | 17,948,653 | $88,127,884 | 0% | |
| 3. | 14,997,234 | $73,636,418 | 0% | |
| 4. | 11,158,139 | $54,786,000 | 0.07% | |
| 5. | 10,176,519 | $49,966,708 | 0% |
News See All
13 Best Biotech Penny Stocks to Buy According to Hedge Funds
Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2024 Earnings Call Transcript
Operator: Welcome to the Ardelyx Fourth Quarter and Fiscal Year 2024 Earnings Call.
12 Best Biotech Penny Stocks To Invest In Now
Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from lower borrowing costs: biotechnology stocks.
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Ardelyx Third Quarter 2024 Earnings Call.
Ardelyx, Inc. (NASDAQ:ARDX) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Ardelyx Second Quarter 2024 Conference Call. All participants will be in listen-only mode. [Operator Instructions].
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript
Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc.
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript
Ardelyx, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.09. Ardelyx, Inc.
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript
Operator: Good day and welcome to the Ardelyx Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
Billionaire Hedge Funds
